Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transition Therapeutics has received clearance from Health Canada to initiate a phase I clinical trial of its promising Alzheimer's disease-modifying therapeutic candidate AZD-103.
Subscribe to our email newsletter
AZD-103 is part of an emerging class of disease-modifying agents that have the potential to both reduce disease progression and improve symptoms such as cognitive function. This unique class of therapeutics is expected to provide significant advantages over the current products on the market, which only treat disease symptoms.
“The initiation of a phase I clinical investigation of one of the most promising disease modifying drug candidates, AZD-103, represents a major step forward for the company and offers a new hope for millions of Alzheimer’s patients and their families seeking relief from this devastating disease,” said Dr Tony Cruz, chairman and CEO of Transition.
The objective of this phase I trial is to evaluate the pharmacokinetics, safety and tolerability of escalating oral doses of AZD-103 in 12 healthy volunteers.